T6300

Degrasyn (WP1130) (WP1130), a specific deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor, also inhibits Bcr/Abl, which is a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT).

Germination-IN-2 (compound 15) is a potent germination inhibitor with an IC50 of 1.3 μM and demonstrates significant anti-germination effects, reducing the germination rate to 3%.

Antitumor agent-72 (compound 6w) is a potent anticancer agent that induces apoptosis by activating caspase-3 and cleaving PARP, making it valuable for cancer research [1].

VEGFR-2-IN-15 (Compound 14b) is a potent VEGFR-2 inhibitor that inhibits the growth of HepG2 cells in the Pre-G1 phase and induces apoptosis.

NMDA receptor potentiator-1 (Compound 1368) is a subunit-selective NMDA receptor enhancer with IC50 values of 4 μM for NR2C and 5 μM for NR2D expression.

NUCC-390 dihydrochloride, a novel and selective CXCR4 receptor agonist, effectively induces the internalization of CXCR4 receptors and acts antagonistically to AMD3100 [1]. This small-molecule compound has demonstrated the ability to facilitate functional nerve recovery following neurodegeneration in vivo [2].

Carbonic anhydrase inhibitor 11 (compound VI) is a potent, selective inhibitor of carbonic anhydrase, targeting CA II (Ki: 40 nM), CA IX (Ki: 39 nM), and CA XII (Ki: 900 nM).

DHU-Se1 is a potent anti-inflammatory agent that stimulates the release of reactive selenium compounds from macrophages and reduces the expression of cellular inflammatory factors such as iNOS and TNF-α. Additionally, DHU-Se1 blocks the polarization of macrophages from M0 to M1, thereby alleviating the inflammatory process.

(S)-PERK-IN-5, the S-enantiomer of PERK-IN-5, is a PERK inhibitor with an IC50 range of 0.101-0.250 μM.

PERK-IN-5 is a highly selective, potent, orally active inhibitor of protein kinase R-like endoplasmic reticulum (ER) kinase (PERK), displaying inhibition with IC50 values of 2 nM for PERK and 9 nM for p-eIF2α. PERK-IN-5 significantly inhibited tumor growth in the 786-O renal cell carcinoma xenograft tumor model.

NF-κB/PON1-IN-1 (Compound 16) is an inhibitor of the NF-κB/PON1 pathway, exhibiting antioxidant activity (IC50: 45.76 μM) and hepatoprotective properties.